Benitec Biopharma (BNTC) Prices 15.54M Share Offering at $1.93/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St climbs as oil slips; SpaceX spectrum deal weighs on telecoms
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment deteriorates further in October
- CoreWeave stock drops on dilution fears and debt concerns
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
- Anthropic launches cyber defense program for infrastructure and open-source
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
August 8, 2023 10:30 PM EDTHAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (Benitec or the Company), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") Silence and Replace platform, today announced the pricing of its underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 15,544,041 shares of common stock. Each share of common stock is being sold together with one common warrant to purchase one share of common stock at... More



